EUVIMEDEUVIMED entdecken
Crossref

Optimizing Prophylactic Anticoagulation in Burns is Associated with Low Incidence of Venous Thromboembolic Complications

A Mokline, Ghabara R, H Fraj, M Ben Saad, L Thabet, AA Messadi

Medical Research Archives · 26.06.2023 · 11 (6)

DOI: 10.18103/mra.v11i6.3960 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 26.06.2023. Verfasst von A Mokline und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venous thromboembolism (VTE) complications in burn patients are often under-diagnosed and potentially serious. Thromboprophylaxis in this population remains controversial.

Objective

Assess the impact of optimizing prophylactic anticoagulation with enoxaparin in burn patients on the incidence of venous thromboembolism (VTE).

Methods

Case-control study conducted in intensive burn care department in Tunisia during 24 months, (February 2018- February 2020). Patients were divided into 2 groups according to the prophylactic anticoagulation modalities: - G1 (Equation) receiving enoxaparine en mg/12H = 22.8 + (3.3 × % TBSA/10) + (1.89 × (weight in kg)/10)) - G2 (No équation) receiving enoxaparine at a dose of 0.5mg/kg, twice daily The goal of prophylactic antifactor Xa level was 0.2- 0.4 IU/ml Results: During study period, 216 patients were included divided into 2 groups: G1 (n= 108) et G2 (n= 108). The groups were comparable in terms of sex, age, weight, burned skin surface and VTE risk. Also, severity of the 2 groups was comparable regarding: smoke inhalation (p=0.46), use of mechanical ventilation (p=0.22), use of catecholamines within 48 hours (p=0.56) and rescue incision (p=0.77). In the equation group, initial dose of enoxaparin was 0.42± 0.12 mg. Target anti Xa was reached at the 1st dosage in 55 patients 55 (50.9%). The median final dose of enoxaparin required to reach the anti Xa target was 52 mg every 12 hours (range, 35-69 mg). No episodes of bleeding, thrombocytopenia, or heparin allergy were documented in either group. The incidence of VTE complications was higher in group 2 than in group 1 (8.3% versus 3.7%; p=0.001 with an OR=1.6 and CI [0.47-1.03]). The length of stay was longer for G2 with a significant difference (30 days vs 22 days; p=0.001). Mortality was the same for two groups.

Conclusion

Optimizing thromboprophylaxis in severely burned patients with enoxaparin, using the enoxaparin dosing eqauation allows to achieve prophylactic anti-Xa level and to reduce risk of VTE complications.

Zitieren

APA

Mokline, A., R, G., Fraj, H., Saad, M. B., Thabet, L., & Messadi, A. (2023). Optimizing Prophylactic Anticoagulation in Burns is Associated with Low Incidence of Venous Thromboembolic Complications. Medical Research Archives, 11(6). https://doi.org/10.18103/mra.v11i6.3960

Vancouver

Mokline A, R G, Fraj H, Saad MB, Thabet L, Messadi A. Optimizing Prophylactic Anticoagulation in Burns is Associated with Low Incidence of Venous Thromboembolic Complications. Medical Research Archives. 2023;11(6). doi:10.18103/mra.v11i6.3960

BibTeX
@article{Mokline2023,
  author = {Mokline, A and R, Ghabara and Fraj, H and Saad, M Ben and Thabet, L and Messadi, AA},
  title = {Optimizing Prophylactic Anticoagulation in Burns is Associated with Low Incidence of Venous Thromboembolic Complications},
  journal = {Medical Research Archives},
  year = {2023},
  volume = {11},
  number = {6},
  doi = {10.18103/mra.v11i6.3960}
}
Kostenlos starten →